Subscribe
www-billionphotos-com-shutterstock-com-judge-court-
www.BillionPhotos.com / Shutterstock.com
8 March 2016Big PharmaDavid Read

Case report: Eli Lilly loses latest Alimta battle

In the latest instalment of the long-running patent dispute between Actavis and Eli Lilly in relation to anti-cancer drug Alimta (pemetrexed disodium), in February 2016 Mr Justice Arnold at the English High Court handed down his judgment on the issues remitted to him by the English Court of Appeal.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
UK Supreme Court to hear Alimta patent dispute
24 March 2016   The UK Supreme Court has said it will hear a patent dispute between Eli Lilly and Allergan centring on cancer drug Alimta.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
UK Supreme Court to hear Alimta patent dispute
24 March 2016   The UK Supreme Court has said it will hear a patent dispute between Eli Lilly and Allergan centring on cancer drug Alimta.

More on this story

Big Pharma
UK Supreme Court to hear Alimta patent dispute
24 March 2016   The UK Supreme Court has said it will hear a patent dispute between Eli Lilly and Allergan centring on cancer drug Alimta.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
Foley & Lardner adds litigation and transaction expert in New York
‘AI curious’ counsel at AZ, Novartis weigh risks and benefits
Trump’s return sparks calls for pro-patent agenda